Skeletal Muscle Phospholipid Metabolism Regulates Insulin Sensitivity and Contractile Function

Running Title: Muscle CEPT1 deficiency and insulin sensitivity

Katsuhiko Funai,1,4* Irfan J. Lodhi,1* Larry D. Spears,1 Li Yin,1 Haowei Song,1 Samuel Klein,2 and Clay F. Semenkovich1,3

1Division of Endocrinology, Metabolism and Lipid Research, 2Division of Geriatrics and Nutritional Science, 3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, 4Departments of Kinesiology and Physiology, East Carolina University, Greenville, NC

*These authors contributed equally.

Corresponding Author:
Clay F. Semenkovich, MD
Washington University School of Medicine
660 South Euclid Avenue
Campus Box 8127
St. Louis, MO 63110
Phone: 314.362.7617
Fax: 314.362.7641
csemenko@dom.wustl.edu

Keywords: Insulin resistance, exercise, phospholipids, type 2 diabetes

3,947 Words
6 Figures
2 Tables
ABSTRACT

Skeletal muscle insulin resistance is an early defect in the development of type 2 diabetes. Lipid overload induces insulin resistance in muscle and alters the composition of the sarcoplasmic reticulum (SR). To test the hypothesis that skeletal muscle phospholipid metabolism regulates systemic glucose metabolism, we perturbed choline/ethanolamine phosphotransferase-1 (CEPT1), the terminal enzyme in the Kennedy pathway of phospholipid synthesis. In C2C12 cells, CEPT1 knockdown altered SR phospholipid composition and calcium flux. In mice, diet-induced obesity, which decreases insulin sensitivity, increased muscle CEPT1 expression. In high-fat fed mice with skeletal muscle-specific knockout of CEPT1, systemic and muscle-based approaches demonstrated increased muscle insulin sensitivity. In CEPT1-deficient muscles, an altered SR phospholipid milieu decreased sarco/endoplasmic reticulum Ca\(^{2+}\) ATPase (SERCA)-dependent calcium uptake, activating calcium-signaling pathways known to improve insulin sensitivity. Altered muscle SR calcium handling also rendered these mice exercise intolerant. In obese humans, surgery-induced weight loss increased insulin sensitivity and decreased skeletal muscle CEPT1 protein. In obese humans spanning a spectrum of metabolic health, muscle CEPT1 mRNA was inversely correlated with insulin sensitivity. These results suggest that high fat feeding and obesity induce CEPT1, which remodels the SR to preserve contractile function at the expense of insulin sensitivity.
Despite the dozens of disorders exacerbated or induced by physical inactivity (1), a sedentary lifestyle has displaced the biologically normal exercise-trained condition in industrialized countries (2). Skeletal muscle contractile function is intrinsically linked to exercise, and exercise deficiency has contributed to the emergence of obesity, type 2 diabetes, and associated co-morbidities as threats to public health. These conditions are associated with systemic insulin resistance (3). Skeletal muscle is a major contributor to insulin-stimulated glucose disposal (4).

We recently reported an unexpected role for skeletal muscle lipogenesis in the pathogenesis of insulin resistance (5). Fatty acid synthase (FAS), the enzyme catalyzing the committed step in de novo lipogenesis, is suppressed in most tissues by a high fat, high calorie diet (6), but the opposite occurs in skeletal muscle. In mice, high fat, high calorie feeding increases skeletal muscle FAS activity, while muscle specific deficiency of FAS protects mice from diet-induced muscle insulin resistance (5). The mechanism responsible for this relationship involves FAS-facilitated synthesis of phosphatidylethanolamine (PE) at the sarcoplasmic reticulum (SR) to maintain sarco/endoplasmic Ca\(^{2+}\) ATPase (SERCA) activity (7,8). In the absence of FAS, altered PE content decreased SERCA activity, increased cytosolic calcium, and triggered calcium- and AMPK-dependent pathways that increase muscle insulin sensitivity (9). Decreased SERCA activity also induced muscle weakness, consistent with previous studies (10,11).

Most PE synthesis in the mammalian SR/ER is mediated by choline/ethanolamine phosphotransferase-1 (CEPT1), the terminal enzyme in the Kennedy pathway of phospholipid synthesis (12) that generates both PE and phosphatidylcholine (PC). Since FAS has been linked to changes in PE content, SR function, and insulin sensitivity, we evaluated the potential role of skeletal muscle CEPT1 in glucose metabolism. Specifically, we perturbed CEPT1 in muscle,
which included the generation of a novel mouse model of muscle-specific CEPT1 deficiency, to
test the hypothesis that skeletal muscle phospholipid metabolism regulates glucose metabolism.
RESEARCH DESIGN AND METHODS

Animals

The local Animal Studies Committee approved protocols. C57BL/6 ES cells were targeted with a vector (European Conditional Mouse Mutagenesis Program) carrying loxP sites flanking exon 3 of mouse *Cept1*. A karyotypically normal clone (of 10 correctly targeted) was injected into B6(Cg)-Tyrc-2J/J blastocysts, chimeric mice were bred with B6(Cg)-Tyrc-2J/J females, then offspring were crossed with Flp recombinase transgenics to remove the neo cassette and yield floxed heterozygous *Cept1* mice (*Cetp1* lox+/wt). Breeding with human α-skeletal actin (HSA)-Cre mice (13) generated CEPT1 muscle knockout (CEPT1-MKO) mice, which were born in expected Mendelian fashion, indistinguishable from their control littermates, and fertile. Floxed mice without Cre were used as controls since previous studies showed no phenotype in Cre only mice. Diets were Purina 4043 control chow or Harlan Teklad TD 88137 high-fat diet.

Lentivirus-mediated Knockdown

Plasmids encoding shRNA for mouse *Cept1* (TRCN0000103317) and *Chpt1* (TRCN0000103294) were from Open Biosystems. Packaging vector psPAX2 (ID #12260), envelope vector pMD2.G (ID #12259) and scrambled shRNA plasmid (ID #1864) were from Addgene. 293T cells in 10 cm dishes were transfected using Lipofectamine 2000 (Invitrogen) with 2.66 µg psPAX2, 0.75 µg pMD2.G, and 3 µg shRNA plasmid. After 48 h, media were collected, filtered using 0.45 µm syringe filters, and used to treat undifferentiated C2C12 cells. After 36 h, target cells were selected with puromycin, then after 48 h cells were differentiated.

Metabolic Phenotyping

Chemistries were analyzed as described in mice fasted for 6 h (5). Leptin (Crystal Chem), adiponectin (B-Bridge International), and insulin (PerkinElmer) ELISAs were performed
according to manufacturers’ instructions. Glucose and insulin tolerance tests (5) were separated by a week. Body composition was determined with an EchoMRI 3-in-1 instrument (Echo Medical Systems). Free water mass was less than 0.1 g for all animals and did not differ by genotype. Indirect calorimetry (Oxymax, Columbus Instruments) was performed as described (5) over 24 h after acclimating mice. Cold tolerance testing was performed by fasting mice for 4 h, then placing animals in a 4°C room for 6 h. Body temperatures were determined at regular intervals with a rectal thermometer (Thermo Fisher).

**Muscle Function Studies**

Mouse forelimb strength was determined using a Rodent Grip Strength Meter (Harvard Apparatus), which records peak force at the time grip is lost. Ten measurements separated by ten min rest periods were recorded, two high and two low extremes were discarded, and the remaining six values were averaged.

Treadmill running utilized a high-intensity protocol as described (14). Fed mice ran 1 min intervals (with 2 min rest periods) beginning at 10 m/min and increasing by 5 m/min at each interval until exhaustion (5 sec at electric grid).

**Whole Body and Muscle-Specific Glucose Metabolism**

Hyperinsulinemic-euglycemic clamps were performed as described (5). For the basal phase, blood samples were obtained, 3-[³H]D-glucose was infused (0.05 µCi/min), then one h later a second basal blood sample was obtained to estimate rate of appearance (Ra) or rate of disappearance (Rd) (Ra = Rd for the basal phase). For the clamp phase, infusion of 3-[³H]D-glucose was replaced with a solution that contained 3-[³H]D-glucose (0.05 µCi/min) and regular human insulin at 2.5 mU/kg/min (with 50 mU/kg prime); D-glucose was infused to maintain blood glucose at 120 mg/dl. After 75 min of steady state blood glucose at 120 mg/dl, a final
blood sample was taken to estimate Ra and Rd during the clamp phase (Ra ≠ Rd for the clamp phase). Insulin-stimulated GDR (IS-GDR) was calculated as (Rd-clamp – Rd-basal). Hepatic glucose production (HGP) suppression was calculated as ([Ra-basal – Ra-clamp] / Ra-basal).

2-deoxyglucose uptake in isolated muscles (15) was performed in paired soleus muscles with one muscle incubated with 100 µU/ml of regular insulin and the other without insulin (basal). Muscles were incubated in Krebs-Henseleit buffer (KHB) + 0.1% bovine serum albumin (BSA) + 2 mM sodium pyruvate + 6 mM mannitol for 15 min, then transferred to a 2nd vial with KHB + 0.1% BSA + 1 mM 2-deoxyglucose (2DG, containing 2-deoxy-[3H]glucose, 6 mCi/mmol) + 9 mM mannitol (containing [14C]mannitol, 0.053 mCi/mmol) for 15 min. Samples were then processed, frozen, homogenized, and 2DG uptake was determined.

**SERCA-Dependent Calcium Uptake**

SR fractions isolated by differential centrifugation (5) from C2C12 myocytes or skeletal muscles were assayed as described (5,16). The reaction was initiated with SR fractions containing 150 µg protein, stopped with 0.15 M KCl/1 mM LaCl₃, and counted after collection on a membrane. SERCA-independent calcium transport was determined by assays in the presence of 10 µM thapsigargin.

**Phospholipid Assays**

Samples reconstituted in ddH₂O were mixed with extraction buffer [2:2(v/v) chloroform/methanol] in the presence of internal standards: 14:0-PC ([M+Li]+ m/z 684.58) or 14:0-PE ([M-H]- m/z 678.62). The organic phase was collected, concentrated to dryness under nitrogen, and reconstituted in methanol. An aliquot was removed, diluted with methanol containing 0.6% LiCl, and analyzed by direct injection ESI-MS on a Thermo Vantage triple-quadrupole mass spectrometer in positive mode for the analysis of PC (neutral loss of 183) species.
Another aliquot was analyzed in negative mode for PE species. Intensities of individual species were compared to internal standards and results were generated using a standard curve.

**PCR and Western Blotting**

Genotyping and mouse/human RT-PCR primers were based on sequences in public databases. For blotting, membranes were incubated with the following primary antibodies: anti-CEPT1 [sc-133421], anti-CaMKI [sc-33165], anti-phospho-CaMKI<sub>Thr177</sub> [sc-28438] from Santa Cruz; anti-CaMKII [#3362], anti-phospho-CaMKII<sub>Thr286</sub> [#3361], anti-AMPKα [#2532], anti-phospho-AMPKα<sub>Thr172</sub> [#2531], anti-Akt [#9272], anti-phospho-Akt<sub>Thr308</sub> [#9275], anti-AS160 [#2447], anti-phospho-AS160<sub>Thr642</sub> [#4228] from Cell Signaling; anti-actin [A2066] from Sigma-Aldrich; anti-OXPHOS cocktail [ab110413] from Abcam. Bands were quantified by densitometry.

**Muscle Analyses**

Fatty acid oxidation was assayed by incubating labeled palmitate with cell or tissue homogenates and quantifying the generation of labeled CO<sub>2</sub> using NaOH-containing filter paper (17). ATP content in extensor digitorum longus (EDL) muscles was measured using a kit from Abcam (ab83355). DAG was quantified using a Thermo Scientific LTQ Orbitrap Velos mass spectrometer after extraction essentially as described (18). For electron microscopy, EDL muscles from fasted mice were fixed in modified Karnovsky’s fixative, post-fixed in buffered osmium tetroxide, stained with uranyl acetate, embedded, sectioned, post-stained with Venable’s lead citrate, and imaged with a JEOL 1299EX electron microscope.

**Human Studies**

Fifty-five obese subjects participated in this study, which was approved by the local Human Research Protection Office. Written informed consent was obtained from all subjects before their participation. These subjects represent a subset of subjects reported previously as part of
other studies (surgical intervention registration: NCT00981500) that obtained muscle tissue samples by percutaneous biopsy and evaluated skeletal muscle insulin sensitivity by using the hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopically labeled glucose tracer, as previously described (19-21). No subject had diabetes or other serious illnesses, none used tobacco, and none were taking medications that impact lipid metabolism.

Statistics

Results are expressed as means ± SEM or means with 95% confidence intervals. Comparisons were performed using an unpaired two-tailed Student t-test (for two-group analyses) or two-way ANOVA with Student-Newman-Keuls post hoc test (for two by two comparisons).
RESULTS

CEPT1 Knockdown in C2C12 Cells

Skeletal muscle FAS deficiency increases insulin sensitivity in mice by activating calcium-dependent signals through the alteration of SR phospholipid composition and SERCA activity (5). These mechanisms were defined in part by studying C2C12 cells, a skeletal muscle-like cell line that models some canonical signaling pathways in mammalian muscle. To determine if CEPT1, a critical enzyme in phospholipid synthesis, represents a lipid signaling node downstream of FAS, we knocked down CEPT1 in C2C12 cells. Lentivirus-mediated knockdown of CEPT1 (Fig. 1A), reported to reside in the ER/SR (12,22) decreased SR phosphatidylethanolamine (PE) content as compared to cells treated with a scrambled virus (Fig. 1B,C). CEPT1 knockdown also resulted in an increase in phosphatidylcholine (PC) (Fig. 1D,E), which nearly doubled the SR PC/PE ratio (Fig. 1F). Mirroring findings with FAS inactivation and reports from others indicating that an increased PC:PE ratio decreases SERCA activity (5,7,8), these changes in SR phospholipids and PC:PE ratio resulted in decreased SERCA-dependent calcium uptake (Fig. 1G) and activation of the calcium signaling proteins CaMKI and CaMKII (Fig. 1H,I). Similar to FAS deficiency, CEPT1 deficiency in C2C12 cells did not alter Akt phosphorylation, but increased phosphorylation of AMPK and AS160, leading to increased pAS160 in response to insulin signaling (Fig. 1J,K). Knockdown of CEPT1 in C2C12 cells did not affect fatty acid oxidation (0.64 ± 0.04 nmol palmitate/mg/h in scrambled vs. 0.58 ± 0.03 in CEPT1 KD, P=0.28). Knockdown of choline phosphotransferase-1 (ChPT1), a PC synthesizing enzyme that resides in the Golgi (12), did not affect phospholipids, SERCA activity, or calcium signaling (Supplementary Fig. 1A-I).
Effects of High-Fat Diet on CEPT1 in Mouse Skeletal Muscle

A tissue survey for CEPT1 protein by Western blotting in wild type C57BL/6 mice showed high expression in liver, soleus muscle, heart, and brown adipose tissue (Fig. 2A). Western blotting of eight different muscles with different physiological characteristics and different fiber-type composition showed higher expression of CEPT1 in soleus and diaphragm (Fig. 2B). Both have a predominance of slow-twitch fibers, which have been linked to diet-induced insulin resistance (23,24). Six weeks of high-fat diet (HFD) feeding, which causes insulin resistance, to C57BL/6 mice increased levels of CEPT1 protein and mRNA (Fig. 2C and D), but not ChPT1 mRNA (Fig. 2E) in soleus muscle. Since high-fat diet feeding in mice is known to alter PC and PE abundance in skeletal muscle (5,25), we fed mice standard chow or high-fat diet and isolated the SR from gastrocnemius muscles. HFD caused proportional increases in both PE (Figure 2F,G) and PC (Figure 2H,I) in SR. There was no difference in the SR PC:PE ratio (a determinant of SERCA activity) or SERCA activity between chow and HFD mice (Fig. 2J,K). These data suggest that in wild type mice, a high-fat diet induces CEPT1 expression and increases PC and PE abundance in skeletal muscle SR, with maintenance of SR calcium handling likely due to maintenance of the SR PC:PE ratio.

Skeletal Muscle-Specific CEPT1 Deficiency in Mice

To determine directly if CEPT1 deficiency improves insulin sensitivity after high-fat diet feeding, we generated CEPT1 muscle-specific knockout (MKO) mice. Human α-skeletal actin (HSA)-Cre, specific for skeletal muscle, was used to target the floxed CEPT1 locus (Fig. 2L,M). CEPT1-MKO mice showed proportional decreases in CEPT1 message and protein in both soleus and EDL muscles (Fig. 2N-P). With chow feeding, CEPT1-MKO and control mice did not differ in body weight, body composition, oxygen consumption (VO₂), respiratory quotient (RQ), GTT,
ITT, circulating metabolites, or major metabolic hormones (Supplementary Fig. 2, Table 1). Like CEPT1-MKO mice, skeletal muscle-specific FAS knockout mice also have no metabolic phenotype with chow feeding (5).

CEPT1-MKO and control mice were challenged with a high-fat diet. After six weeks, body weight (Fig. 3A), body composition (Fig. 3B), circulating metabolites, hormones, tissue weights (Table 1) and VO₂ (Fig. 3C) did not differ between genotypes. However, RQ during dark cycles was increased in CEPT1-MKO compared to control mice (Fig. 3D), suggesting increased utilization of glucose by CEPT1-MKO mice when these nocturnal animals are eating.

**CEPT1-MKO Mice are Protected from Diet-induced Insulin Resistance**

Glucose and insulin tolerance testing showed that high-fat fed mice with skeletal muscle CEPT1 deficiency had improved glucose tolerance (Fig. 3E) and lower blood glucose after insulin administration (Fig. 3F) compared to controls. To clarify site-specific effects on insulin sensitivity, hyperinsulinemic-euglycemic clamp studies were conducted in high-fat diet fed CEPT1-MKO and control mice (Fig. 3G-J). Consistent with GTT and ITT results in these animals, the glucose infusion rate (GIR), an indicator of whole-body insulin sensitivity, was two-fold greater in CEPT1-MKO compared to control mice (Fig. 3G). The insulin-stimulated glucose disposal rate (IS-GDR), an indicator of peripheral insulin sensitivity, was also two-fold greater in CEPT1-MKO compared to control mice (Fig. 3I). There was no genotype-specific effect on insulin suppression of endogenous (mostly hepatic) glucose production (HGP suppression, Fig. 3J).

Enhanced insulin sensitivity occurred without effects on adiposity (Fig. 3B), serum FFA, adiponectin, or leptin concentrations (Table 1), or metabolic rate (Fig. 3C), suggesting that muscle CEPT1 deficiency increased insulin sensitivity through effects intrinsic to muscle. To
address directly the potential role of muscle in the phenotype, soleus muscles isolated from high-fat fed CEPT1-MKO and control mice were incubated in the presence of 2-deoxyglucose with or without 100 µU/mL insulin. Insulin-stimulated 2-deoxyglucose uptake in CEPT1-MKO muscle was greater than in control muscle (Fig. 3K,L). Western blotting showed that calmodulin-dependent kinase I (CaMKI) and AMPK were activated in CEPT1-MKO muscle as compared to control muscle, but there was no genotype-specific effect on Akt (Fig. 3M,N). AMPK activation would be expected to increase phosphorylation of acetyl-CoA carboxylase (ACC) and AS160, both seen in CEPT1-MKO muscles (Fig. 3M,N), effects associated with increased insulin sensitivity. This same pattern of calcium-activated signaling with no effect on Akt was also seen in muscle-specific FAS knockout mice (5), suggesting that FAS and CEPT1 regulate muscle insulin sensitivity through similar mechanisms.

**Muscle CEPT1 Deficiency is Associated with Altered SR Phospholipid Composition, Disrupted Calcium Handling, and Weakness**

FAS deficiency in C2C12 cells as well as in skeletal muscle alters the SR PC:PE ratio to decrease SERCA activity (5), and CEPT1 deficiency in C2C12 cells similarly increases SR PC:PE and decreases SERCA activity (Fig. 1), so we characterized SR phospholipids and SERCA activity in gastrocnemius muscle of MKO mice. Muscle CEPT1 deficiency in high-fat fed mice reduced SR PE (Fig. 4A,B), and increased several SR PC species (Fig. 4C,D), which increased the SR PC/PE ratio (Fig. 4E). This membrane composition change reduced SERCA-dependent calcium uptake in CEPT1 deficient muscles (Fig. 4F).

Intact SR calcium handling is required for normal muscle strength (26). Mimicking the effects in high-fat fed mice with skeletal muscle FAS deficiency (5), HFD CEPT1-MKO mice had decreased performance compared to control mice during high intensity exercise tests (Fig.
4G,H), and had weaker forelimb grip strength than control mice (Fig. 4I,J). Altered SERCA activity in muscle has been reported to affect thermogenesis (27), but there was no body temperature difference between HFD-fed MKO and control mice in cold tolerance tests (Fig. 4K).

CEPT1, DAG, and Mitochondria

FAS deficiency does not appear to alter mitochondrial function in skeletal muscle (5), but mice with deletion of CTP:phosphoethanolamine cytidylyltransferase (ECT), the ethanolamine-specific enzyme directly upstream of CEPT1 in the Kennedy pathway, have a profound mitochondrial phenotype and increased diacylglycerol (DAG) content (28). Protein content of mitochondrial respiration complex I-IV (Fig. 5A,B), gene expression of mitochondrial biogenesis markers (Fig. 5C), and levels of fatty acid oxidation (Fig. 5D) did not differ between gastrocnemius muscles from HFD-fed control and CEPT1-MKO mice. DAG content (Fig. 5E,F), ATP content (Fig. 5G), and apparent mitochondrial density as determined by electron microscopy (Fig. 5H) did not differ between muscles from chow-fed control and CEPT1-MKO mice.

CEPT1 in Human Skeletal Muscle

To determine if skeletal muscle CEPT1 is related to lipid metabolism and insulin resistance in humans, we studied CEPT1 in skeletal muscle biopsies from two human cohorts. In the first cohort, muscle was obtained from 16 subjects before and after ~20% weight loss, induced by Roux-en-Y gastric bypass or laparoscopic adjustable gastric banding. This intervention decreased adiposity and insulin resistance (Table 2A). Skeletal muscle CEPT1 protein abundance was decreased after surgery-induced weight loss (Fig. 6A with blots from two representative subjects shown above the graph), suggesting that muscle CEPT1 expression is increased in the human obese state, a finding that parallels the increase in CEPT1 expression seen in mice with
HFD feeding (Fig. 2C,D). Moreover, surgery-induced changes in muscle CEPT1 protein abundance were correlated with surgery-induced changes in glucose Rd (Fig. 6B), but not with surgery-induced changes in fat mass (Fig. 6C). In the second human cohort, muscle biopsies were obtained from obese subjects (Table 2B) representing a range in skeletal muscle insulin sensitivity as assessed by glucose Rd during a hyperinsulinemic-euglycemic clamp procedure. Skeletal muscle \textit{CEPT1} mRNA levels were inversely correlated with glucose Rd (Fig. 6D), suggesting that lower levels of muscle CEPT1 are associated with improved insulin sensitivity in the setting of human obesity, a finding that parallels the improved insulin sensitivity seen in muscle CEPT1 deficient mice fed a high-fat diet (Fig. 3F,I,K).
DISCUSSION

How excess lipids interact with muscle to affect glucose metabolism is poorly understood. Caloric excess and physical inactivity promote hyperlipidemia and lipid deposition in skeletal muscle (29), leading to increased lipid content that is associated with insulin resistance (30). However, insulin-sensitive trained athletes also have lipid-laden muscles (18,31), an observation difficult to reconcile with findings in insulin-resistant muscle despite elegant studies of diacylglycerols (32), acylated molecules (33-35), and ceramides (36). To provide novel insights into the complex relationship between lipid excess and insulin sensitivity, we tested the hypothesis that skeletal muscle phospholipid metabolism regulates glucose metabolism.

Our results show that lipid overload in the form of high fat feeding to mice and obesity in humans is associated with increased expression of CEPT1. High-fat diet induction of CEPT1 in mice increased phospholipid content of skeletal muscle, and disruption of CEPT1 in either cells or mice resulted in phospholipid compositional changes linked to decreased activity of SERCA, which sequesters calcium in the SR to preserve muscle strength. High-fat fed mice with skeletal muscle-specific CEPT1 deficiency had increased insulin sensitivity due to increased glucose transport into muscle. The muscle-specific CEPT1 deficient animals were weak, consistent with decreased SERCA activity.

Our findings in mice have potential translational relevance. CEPT1 mRNA levels are inversely correlated with insulin sensitivity, and weight loss in obese humans decreases skeletal muscle CEPT1 protein. The latter change correlated with insulin sensitivity but not fat mass, suggesting that CEPT1 and its products, as opposed to potentially toxic effects of other lipids, may play a role in human insulin resistance.
These results suggest that lipid excess induces SR phospholipid adaptation in skeletal muscle, and implicates CEPT1 as an important enzyme for maintaining SR functional integrity. The SR releases calcium to allow contraction, and sequesters calcium through the activity of SERCA to allow relaxation. Our data show that high-fat diet feeding increases SR phospholipid abundance, mediated in part by an induction of CEPT1 that preserves the PC:PE ratio, a known determinant of SERCA activity (7,37). In the absence of muscle CEPT1, an increased PC:PE ratio decreases SERCA activity, causing muscle weakness (26).

Both CEPT1 and FAS increase in muscle with high-fat feeding. Muscle CEPT1 deficiency appears to mirror muscle FAS deficiency (5). Both models have a normal phenotype on a chow diet, and both develop the same degree of adiposity as littermate controls with high-fat feeding. Diet-induced obesity in mice with deficiency of CEPT1 or FAS in muscle resulted in increased insulin sensitivity. The latter is likely caused by altered calcium flux. Increased cystosolic calcium signaling, seen with both CEPT1 and FAS deficiency, is a known muscle insulin sensitizer (9,38-41). One interpretation of the similarities between the FAS deficient and CEPT1 deficient phenotypes in muscle is that FAS and CEPT1 coordinately channel lipids to compartments responsible for maintaining contractile function in the setting of high-fat feeding. High-fat diets compromise exercise performance (42-44), suggesting that FAS-CEPT1 lipid channeling may compensate for detrimental dietary effects on muscle function. Lipid compartmentalization in muscle is known to occur with acyl-CoA molecules (45).

Muscle FAS deficiency and CEPT1 deficiency are independently characterized by selective decreases in SR PE content only in the setting of high-fat feeding, consistent with the notion that FAS and CEPT1 coordinately channel lipids since either deficiency impacts the same class of lipids at the same site. Since PE increases the affinity of calcium for SERCA in lipid
bilayers (8), decreasing its content in the setting of CEPT1 or FAS deficiency provides a molecular explanation underlying impaired SERCA activity with an altered PC:PE ratio. Increasing SERCA1 expression restores SERCA enzyme activity and eliminates AMP activation caused by FAS deficiency (5), suggesting that SERCA activity is more important than the PC:PE ratio for insulin action. Neither FAS nor CEPT1 deficiency appears to impact mitochondrial function, which might be predicted based on previous data suggesting that mitochondrial PE is generated on the mitochondrial inner membrane through the action of phosphatidylserine carboxylase (46,47).

While this work was in preparation, ECT-deficient mice were described (28). Like FAS and CEPT1 deficiency with low fat feeding, these animals have no insulin sensitivity phenotype on a chow diet. Unlike the FAS and CEPT1 models, these mice have a mitochondrial phenotype, perhaps due to forced reliance on the activity of phosphatidylserine carboxylase to generate the PE detected in these animals. Other features complicate comparisons between the different models. The ECT-deficient mouse was generated using the MCK (muscle creatine kinase) Cre, expressed in adult heart (48), suggesting that altered myocardial function could impact skeletal muscle metabolism through altered perfusion. FAS and CEPT1 deficient mice were generated using HSA Cre, which is not expressed in adult heart (5). Lipid channeling involving FAS and CEPT1 is likely because FAS is substantially associated with SR in muscle (5) and CEPT1 is predominantly an SR/ER enzyme. ECT, unlike the choline-specific enzyme directly upstream of CEPT1 in the Kennedy pathway, appears to be predominantly cytosolic (49), suggesting that only a subfraction of this enzyme at the SR would be required for directed lipid synthesis.

In summary, the loss of muscle CEPT1 in mice increases insulin sensitivity but impairs muscle strength in the setting of a high-fat diet. In obese humans, weight loss decreases CEPT1
protein and these changes are correlated with insulin sensitivity but not fat mass. In a separate group of humans, skeletal muscle CEPT1 mRNA was inversely associated with insulin sensitivity. The phenotypes of skeletal muscle-specific CEPT1 deficiency and skeletal muscle-specific FAS deficiency appear to be the same, suggesting that these lipogenic proteins participate in the channeling of lipids to PE pools at the SR. The coordinate induction of FAS and CEPT1 in muscle in the setting of insulin resistance may be required to maintain muscle functional integrity. Identifying specific PE species linked to muscle function in humans could lead to novel therapies for sustaining muscle contraction in the obese, a strategy that could promote health.

**FUNDING**

This work was funded by NIH grants DK101392, DK076729, DK020579, DK056341, DK094874, DK095505, and DK095774 (the last two to K.F).

**DUALITY OF INTEREST**

No potential conflicts of interest relevant to this article were reported by each author.

**AUTHOR CONTRIBUTIONS**

K.F. designed experiments, contributed to all data unless otherwise noted, and wrote the manuscript. I.J.L. conceived the experiment and generated floxed CEPT1 mice. L.D.S. assayed DAG and ATP in muscle, processed samples for electron microscopy, and performed hyperinsulinemic-euglycemic clamp studies. L.Y. performed hyperinsulinemic-euglycemic clamp studies. H.S. conducted phospholipidomic analyses. S.K. contributed to study design, generated data involving humans, and revised the manuscript. C.F.S. designed experiments and wrote the manuscript. K.F. is the guarantor of this work and, as such, had full access to all the
data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PRIOR PRESENTATION

Parts of this study were presented as a poster at the American Diabetes Association Annual Scientific Sessions, San Francisco, CA, June 13-17, 2014.

REFERENCES

9. Wright DC, Hucker KA, Holloszy JO, Han DH: Ca2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes 2004;53:330-335


33. Li LO, Klett EL, Coleman RA: Acyl-CoA synthesis, lipid metabolism and lipotoxicity. Biochim Biophys Acta 2010;1801:246-251


41. Park DR, Park KH, Kim BJ, Yoon CS, Kim UH: Exercise ameliorates insulin resistance via Ca2+ signals distinct from those of insulin for GLUT4 translocation in skeletal muscles. Diabetes 2015;64:1224-1234


### Table 1. Chow diet and high-fat diet fed control and CEPT1-MKO (MKO) mice

<table>
<thead>
<tr>
<th></th>
<th>Chow Control</th>
<th>Chow MKO</th>
<th>HFD Control</th>
<th>HFD MKO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dl)</td>
<td>123.7 ± 5.3</td>
<td>131.7 ± 8.9</td>
<td>205.4 ± 12.5*</td>
<td>204.8 ± 10.5*</td>
</tr>
<tr>
<td>Free Fatty Acids (mM)</td>
<td>0.434 ± 0.048</td>
<td>0.394 ± 0.047</td>
<td>0.556 ± 0.043*</td>
<td>0.565 ± 0.036*</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>35.92 ± 3.66</td>
<td>37.32 ± 1.92</td>
<td>54.81 ± 3.09*</td>
<td>53.64 ± 2.41*</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>58.5 ± 9.8</td>
<td>52.1 ± 6.1</td>
<td>162.4 ± 12.1*</td>
<td>155.2 ± 15.8*</td>
</tr>
<tr>
<td>Insulin (µU/ml)</td>
<td>4.6 ± 0.9</td>
<td>5.0 ± 1.7</td>
<td>11.8 ± 1.8*</td>
<td>12.3 ± 1.9*</td>
</tr>
<tr>
<td>Leptin (ng/ml)</td>
<td>1.4 ± 0.6</td>
<td>1.1 ± 0.5</td>
<td>5.8 ± 1.1*</td>
<td>6.3 ± 1.4*</td>
</tr>
<tr>
<td>Adiponectin (µg/ml)</td>
<td>27.5 ± 2.4</td>
<td>28.2 ± 3.6</td>
<td>25.7 ± 3.9</td>
<td>25.1 ± 4.1</td>
</tr>
<tr>
<td>Soleus Weight (mg)</td>
<td>10.25 ± 0.44</td>
<td>10.65 ± 0.53</td>
<td>11.13 ± 0.69</td>
<td>11.36 ± 0.49</td>
</tr>
<tr>
<td>EDL Weight (mg)</td>
<td>11.92 ± 0.63</td>
<td>12.13 ± 0.57</td>
<td>12.33 ± 0.53</td>
<td>12.22 ± 0.62</td>
</tr>
<tr>
<td>Liver Weight (g)</td>
<td>0.568 ± 0.035</td>
<td>0.577 ± 0.041</td>
<td>1.182 ± 0.061*</td>
<td>1.128 ± 0.066*</td>
</tr>
<tr>
<td>Epididymal Fat Weight (g)</td>
<td>0.468 ± 0.048</td>
<td>0.492 ± 0.033</td>
<td>1.313 ± 0.055*</td>
<td>1.293 ± 0.071*</td>
</tr>
</tbody>
</table>

N=6-12/experimental group. Data are means ± SEM. *By two-way ANOVA, there is a main effect (P≤0.0035) of HFD on all variables except adiponectin, soleus weight, and EDL weight.
Table 2. Characteristics of the human subjects

A. Subjects before and after bariatric surgery-induced weight loss (N=16)

<table>
<thead>
<tr>
<th></th>
<th>Surgery (Male/Female)</th>
<th>RYGB (2/5), LAGB (1/8)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>46.0 [40.2 – 51.7]</td>
<td></td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td>132.9 [117.7 – 148.1]</td>
<td>107.4 [95.1 – 119.7] *</td>
</tr>
<tr>
<td>Body Mass Index (kg/m²)</td>
<td>46.4 [42.3 – 50.5]</td>
<td>37.5 [34.2 – 40.7] *</td>
</tr>
<tr>
<td>Body Fat (%)</td>
<td>51.3 [48.7 – 53.8]</td>
<td>46.3 [43.4 – 49.2] *</td>
</tr>
<tr>
<td>Intrahepatic Triglyceride Content (%)</td>
<td>12.2 [8.2 – 16.3]</td>
<td>3.9 [2.1 – 5.8] *</td>
</tr>
<tr>
<td>Fasting Blood Glucose (mg/dl)</td>
<td>95.3 [90.9 – 99.7]</td>
<td>86.3 [83.3 – 89.4] *</td>
</tr>
<tr>
<td>Fasting Blood Insulin (µU/ml)</td>
<td>23.9 [20.2 – 27.7]</td>
<td>9.1 [7.7 – 10.6] *</td>
</tr>
<tr>
<td>Glucose Rₜ (µmol/min/kg FFM)</td>
<td>Basal 16.4 [15.3 – 17.5]</td>
<td>15.2 [14.1 – 16.3]</td>
</tr>
<tr>
<td></td>
<td>Clamp 36.7 [30.2 – 43.1]</td>
<td>57.4 [50.6 – 64.1] *</td>
</tr>
</tbody>
</table>

Data are means [95% confidence intervals]. *P<0.05. RYGB is Roux-en-Y gastric bypass. LAGB is laparoscopic adjustable gastric banding. Rₜ is rate of disappearance from plasma. FFM is fat free mass.

B. Obese subjects with varying metabolic health (N=39)

<table>
<thead>
<tr>
<th>Subject Number</th>
<th>6 (Male), 33 (Female)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>40.2 [36.6 – 43.8]</td>
</tr>
<tr>
<td>Body Weight (kg)</td>
<td>95.3 [87.3 – 103.2]</td>
</tr>
<tr>
<td>Body Mass Index (kg/m²)</td>
<td>33.5 [30.9 – 36.1]</td>
</tr>
<tr>
<td>Body Fat (%)</td>
<td>43.4 [40.6 – 46.3]</td>
</tr>
<tr>
<td>Visceral Adipose Tissue (cm³)</td>
<td>1341.6 [1087.1 – 1596.2]</td>
</tr>
<tr>
<td>Intrahepatic Triglyceride Content (%)</td>
<td>8.45 [5.39 – 11.51]</td>
</tr>
<tr>
<td>Fasting Blood Glucose (mg/dl)</td>
<td>93.0 [90.9 – 95.2]</td>
</tr>
<tr>
<td>Fasting Blood Insulin (µU/ml)</td>
<td>15.36 [12.47 – 18.26]</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>3.57 [2.87 – 4.26]</td>
</tr>
<tr>
<td>Fasting Blood Free Fatty Acids (µM)</td>
<td>0.56 [0.52 – 0.61]</td>
</tr>
</tbody>
</table>

Data are means [95% confidence intervals]
FIGURE LEGENDS

Figure 1. CEPT1 knockdown increases sarcoplasmic reticulum (SR) phosphatidylcholine:phosphatidylethanolamine ratio, calcium signaling, and insulin action in C2C12 cells. (A) CEPT1 gene expression in C2C12 cells treated with scrambled (SC, the control) or CEPT1 knockdown (CEPT1KD) shRNA. (B-F) SR phospholipid composition for SC and CEPT1KD C2C12 cells. (B) Total SR phosphatidylethanolamine (PE). (C) SR PE species. (D) Total SR phosphatidicholine (PC). (E) SR PC species. (F) SR PC:PE ratio. (G) SERCA-dependent calcium uptake in SC and CEPT1KD C2C12 cells. (H-K) Western blots and quantification of proteins for SC and CEPT1KD C2C12 cells. SERCA: sarco/endoplasmic reticulum Ca$^{2+}$ ATPase. n=4-6/experimental condition. Data are means ± SEM. * P<0.05. †P<0.05 vs. SC.

Figure 2. High-fat diet increases mouse muscle CEPT1 but does not alter sarcoplasmic reticulum (SR) phosphatidylcholine (PC):phosphatidylethanolamine(PE) ratio or SERCA activity, and the generation of CEPT1-MKO mice. (A) CEPT1 protein content in multiple tissues. (B) CEPT1 protein content in multiple muscles. (C-K) CEPT1 expression, muscle SR phospholipids and SERCA activity in chow-fed and HFD-fed C57BL/6 mice, n=5-8/experimental group. (C) CEPT1 protein abundance in soleus. (D) CEPT1 mRNA abundance in soleus. (E) ChPT1 mRNA abundance in soleus. (F-J) Phospholipid analyses in gastrocnemius muscles. (F) Total SR phosphatidylethanolamine (PE). (G) SR PE species. (H) Total SR phosphatidylcholine (PC). (I) SR PC species. (J) SR PC:PE ratio. (K) SERCA-dependent calcium uptake. (L) Strategy yielding CEPT1-MKO mice. (M) Genotyping PCR for wild type (WT), heterozygous knockout in muscle

Figure 3. HFD-fed CEPT1-MKO mice are protected from diet-induced skeletal muscle insulin resistance. (A) Body weight, n=7/experimental group. (B) Body composition by MRI, n=9/experimental group. (C) Oxygen consumption, n=5/experimental group. (D) Respiratory quotient, n=5-6/experimental group. (E) Glucose tolerance testing. Area under the curve (AUC) quantification is provided as an insert, n=10/experimental group. (F) Insulin tolerance testing. AUC quantification is provided as an insert, n=6-7/experimental group. (G-J) Hyperinsulinemic-euglycemic clamp studies, n=4/experimental group. (G) Glucose infusion rate (GIR). (H) Glucose disposal rate (GDR). (I) Insulin-stimulated glucose disposal rate (IS-GDR). (J) Hepatic glucose production (HGP) suppression. (K-N) Studies of isolated soleus muscles, n=6/experimental group. (K) 2-deoxyglucose uptake in basal and insulin-stimulated soleus. (L) Δ-2-deoxyglucose uptake was calculated by subtracting values of 2-deoxyglucose uptake in basal muscles from values of 2-deoxyglucose uptake in insulin-stimulated muscles. (M-N) Western blot quantification of incubated soleus muscles under basal or insulin-stimulated conditions. Data are means ± SEM. * P<0.05. †P<0.05 vs. Ctrl.
Figure 4. HFD-fed CEPT1-MKO mice have increased sarcoplasmic reticulum (SR) phosphatidylcholine (PC):phosphatidylethanolamine (PE) ratio, decreased SERCA activity, and decreased muscle contractile function. (A-E) SR phospholipid composition from gastrocnemius muscles, n=4/experimental group. (A) Total SR PE. (B) Individual SR PE species. (C) Total SR PC. (D) Individual SR PC species. (E) SR PC:PE ratio. (F) SERCA-dependent calcium uptake in gastrocnemius muscles, n=8/experimental group. (G-H) High-intensity graded exercise treadmill testing, n=6/experimental group. (G) Total running time. (H) Total running distance. (I-J) Forelimb grip strength test, n=5-7/experimental group. (I) Absolute forelimb strength. (J) Relative forelimb strength. (K) Cold tolerance test, n=5/experimental group. Data are means ± SEM. * P<0.05.

Figure 5. Muscle CEPT1 deficiency in mice does not affect mitochondrial phenotypes or diacylglycerol (DAG) content. (A-D) Measurements in muscles from HFD-fed mice, n=6/experimental group. (A-B) Western blot quantification of mitochondrial complex I-V in gastrocnemius muscles. (C) Expression of genes involved in mitochondrial biogenesis in gastrocnemius muscles. (D) Rates of fatty acid oxidation in gastrocnemius muscles. (E-F) DAG content in soleus muscle of chow fed mice, n=7/experimental group. (E) Total DAG content. (F) DAG species. (G) ATP content in EDL muscles of chow fed mice, n=4/experimental group. (H) Representative EM images at varying magnification from EDL muscles of chow fed mice. Three animals for each genotype were examined for these studies. Bars in micrographs indicate 500 nm for 25,000X, and 2 µm for 12,000X and 5,000X. Data are means ± SEM. None of the comparisons were statistically significant.
Figure 6. Human muscle CEPT1 is associated with obesity-induced insulin resistance. (A-C) Human muscle CEPT1 protein abundance in 16 subjects (see Table 2A for characteristics) pre- and post-gastric bypass surgery. (A) Western blot quantification of muscle CEPT1 protein. Data are means ± SEM. * P<0.05. (B) Pearson correlation analysis between changes in muscle CEPT1 protein abundance and changes in glucose disposal rate. (C) Pearson correlation analysis between changes in muscle CEPT1 protein abundance and changes in fat mass. (D) Pearson correlation analysis of human muscle CEPT1 mRNA expression and glucose disposal rate determined by clamp for 39 obese subjects of varying metabolic health (see Table 2B for characteristics).
Figure 3

A

Body weight (g)

Ctrl  MKO

B

Weight (g)

Ctrl  MKO

C

VO₂ (mL/min/kg)

Ctrl  MKO

D

RQ

Ctrl  MKO

E

Glucose (mg/dL)

Time (min)

Ctrl  MKO

F

Glucose (% initial)

Time (min)

Ctrl  MKO

G

GluC (μg/mg/min)

Ctrl  MKO

H

GDPR (mg/kg/min)

Ctrl  MKO

I

15-GDPR (mg/kg/min)

Ctrl  MKO

J

HGP suppression (%)

Ctrl  MKO

K

2-deoxyglucose uptake (μg/g)

Basal  Insulin

L

Δ 2-deoxyglucose uptake (μg/g/15 min)

Ctrl  MKO

M

Protein expression

N

Protein phosphorylation (Relative Units)

256x309mm (300 x 300 DPI)
Figure 4

A

B

C

D

E

F

G

H

I

J

K

Diabetes

205x199mm (300 x 300 DPI)
Figure 5

![Graphs and images related to diabetes research]

252x180mm (300 x 300 DPI)
Figure 6

A

B

C

D

198x208mm (300 x 300 DPI)
Supplementary Figure 1. ChPT1 knockdown does not affect sarcoplasmic reticulum phospholipid composition or SERCA activity in C2C12 cells. (A) ChPT1 gene expression in C2C12 cells treated with scrambled (SC, the control) or ChPT1 knockdown (ChPT1KD) shRNA. (B-F) Sarcoplasmic reticulum (SR) phospholipid composition of SC and ChPT1KD C2C12 cells. (B) Total SR phosphatidylethanolamine (PE). (C) SR PE species. (D) Total SR phosphatidylcholine (PC). (E) SR PC species. (F) SR PC:PE ratio. (G) SERCA-dependent calcium uptake in SC and ChPT1KD C2C12 cells. (H-I) Western blot quantification of SC and ChPT1KD C2C12 cells. n=4/experimental condition. Data are means ± SEM. *P<0.05.
Supplementary Figure 2. Chow-fed CEPT1-MKO mice do not manifest an overt metabolic phenotype. (A) Body weight, n=7/experimental group. (B) Body composition, n=7/experimental group. (C) Oxygen consumption, n=5/experimental group. (D) Respiratory quotient, n=5/experimental group. (E) Glucose tolerance test, n=6/experimental group. (F) Insulin tolerance test, n=6/experimental group. (G-K) Sarcoplasmic reticulum (SR) phospholipid composition of gastrocnemius muscles, n=4/experimental group. (G) Total SR phosphatidylethanolamine (PE). (H) SR PE species. (I) Total SR phosphatidylcholine (PC). (J) SR PC species. (K) SR PC:PE ratio. (L) SERCA-dependent calcium uptake in gastrocnemius muscles. n=6/experimental group. (M) Western blot quantification in soleus muscles, n=6/experimental group. Data are means ± SEM. * P<0.05.